Increase of targeted anticancer therapies led to the beginning of a new era of cancer treatment, partly instead of classical chemotherapies, partly supplementing these.While for a number of substances only clinical experiences are relevant for treatment decisions, for some major cancer groups predictive markers are known indicating probably tumor responses.To identify the latter, a need for companion diagnostics is given, sometimes existing as pretherapeutic immunohistochemical or genetic testing.